Can Amlodipine Cause Tachycardia (Heart Racing)?
Amlodipine typically does NOT cause tachycardia (heart racing) at therapeutic doses, which distinguishes it from other dihydropyridine calcium channel blockers. In fact, this lack of reflex tachycardia is one of amlodipine's key clinical advantages.
Mechanism and Clinical Evidence
Amlodipine is a long-acting dihydropyridine calcium channel blocker that causes peripheral vasodilation. While most dihydropyridines (like nifedipine) trigger reflex tachycardia due to rapid vasodilation and sympathetic activation, amlodipine's slow onset and long half-life (30-50 hours) prevent the abrupt blood pressure drops that typically trigger compensatory heart rate increases 1.
Key Supporting Evidence:
Multiple studies confirm no reflex tachycardia: Research directly comparing amlodipine to other calcium channel blockers shows that amlodipine does not increase heart rate, while nifedipine retard significantly increased heart rate (+3.3 beats/min) and sympathetic activity 2.
Autonomic nervous system effects: Unlike nifedipine, amlodipine does not alter parasympathetic activity or sympathovagal balance during 24-hour monitoring 2. A mid-term study over 24 weeks demonstrated that amlodipine "does not cause reflex tachycardia even in mid-term therapy" 3.
Exercise studies: In healthy volunteers performing strenuous treadmill exercise, amlodipine caused only a modest increase in resting heart rate (from 65 to 70 bpm) but did not alter post-exercise heart rate responses 4.
FDA labeling: The official drug label states that "chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate" 1.
Important Clinical Caveats
When Tachycardia MIGHT Occur:
Overdose situations: In severe amlodipine overdose with marked hypotension, reflex tachycardia is expected 1, 5. Paradoxically, some overdose cases have presented with bradycardia rather than tachycardia 5, 6.
Initial dosing: A small increase in resting heart rate (approximately 5 bpm) may occur when starting therapy, but this is clinically insignificant 4.
Individual variation: The FDA label notes that "arrhythmia (irregular heartbeat)" and "heart palpitations (very fast heartbeat)" are possible side effects, though uncommon 1.
Comparison to Other Calcium Channel Blockers
Amlodipine is specifically recommended in guidelines when other dihydropyridines should be avoided due to their tachycardic effects:
The 2002 European Heart Journal guidelines explicitly state: "Nifedipine, or other dihydropyridines, should not be used without concomitant beta-blocker therapy" in acute coronary syndromes 7.
In contrast, amlodipine appeared safe in severe systolic heart failure trials (PRAISE) without causing problematic tachycardia 8, 9.
The 2017 Canadian guidelines note that while most calcium channel blockers should be avoided in heart failure, "amlodipine may be considered for other indications such as persistent hypertension or angina" 9.
Clinical Bottom Line
If a patient reports "heart racing" while on amlodipine at therapeutic doses, look for alternative explanations such as:
- Anxiety or panic
- Concurrent medications or stimulants
- Underlying arrhythmias
- Dehydration or volume depletion
- Thyroid dysfunction
The heart racing is unlikely to be directly caused by amlodipine itself, as this drug's pharmacokinetic profile specifically avoids the reflex tachycardia seen with shorter-acting dihydropyridines 10, 2, 11.